Bone News and Research

RSS

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis.The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

19 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

Study: Half of Canadians with osteoporosis have insufficient levels of vitamin D

New data presented today at the American Society for Bone and Mineral Research 2010 Annual Meeting held in Toronto, Ontario, demonstrated that approximately half of Canadians with osteoporosis have insufficient levels of vitamin D (less than 80 nmol/L), despite the fact that more than 40 per cent are prescribed at least 2800 IU of vitamin D per week.

19 Oct 2010

Study indicates vitamin D deficiency may increase lung transplant rejection

Vitamin D deficiency is associated with a significant increase in lung transplant rejection, according to research conducted at Loyola University Health System (LUHS). These data were presented Monday at The American Society for Bone and Mineral Research 2010 annual meeting in Toronto, Ontario.

19 Oct 2010

IBD patients with Vitamin D deficiency at greater risk of osteoporosis, osteopenia

Vitamin D deficiency puts patients with Inflammatory Bowel Disease (IBD) at greater risk of osteoporosis, osteopenia and an overall higher rate of abnormal bone density, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.

18 Oct 2010

FDA grants fast track designation for Aastrom's CLI cell therapy development program

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted fast track designation for the company's critical limb ischemia (CLI) cell therapy development program. Aastrom plans to initiate Phase 3 clinical testing of its treatment for CLI in early 2011.

18 Oct 2010

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Eli Lilly and Company today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.

18 Oct 2010

Nanotope enters agreement with Smith & Nephew to develop cartilage regeneration product

Arrowhead Research Corporation today announced that its portfolio company, Nanotope, Inc., has entered into an agreement with Smith & Nephew, Inc., a member of the Smith & Nephew plc group to develop a cartilage regeneration product for human healthcare markets using a subset of its proprietary regenerative medicine technology.

18 Oct 2010

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.

18 Oct 2010

Women with normal bone mineral density at age 67 don't need osteoporosis screening again for 10 years

Since 2002, the U.S. Preventive Services Task Force has recommended that women ages 65 and older be routinely screened for osteoporosis and has suggested that a 2-year screening interval might be appropriate. However, what length the screening interval should be is a topic that remains controversial and undecided, with no definitive scientific evidence to provide guidance.

18 Oct 2010

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

18 Oct 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis. The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

18 Oct 2010

$Spinal fractures remain undiagnosed and untreated$

Spinal fractures remain undiagnosed and untreated

A new report issued by the International Osteoporosis Foundation (IOF) for World Osteoporosis Day puts the spotlight on the severe impact of spinal fractures and calls on health professionals to recognize the signs of these fractures in their patients.

15 Oct 2010

CoreLab offers state-of-the-art imaging solutions for DXA imaging sciences

CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm Inc. and Medifacts International in February of this year, has launched a full suite of imaging service solutions and quality assurance processes as it relates to Dual Energy X-Ray Absorptiometry (DXA).

15 Oct 2010

Childhood obesity impacts musculoskeletal system

An epidemic of childhood obesity can have a devastating impact on a child's musculoskeletal system, the U.S. Bone and Joint Decade says. Extra weight stresses growing bones, causing pain and interfering with normal growth and development.

15 Oct 2010

DFG to establish new Research Units

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing four new Research Units to facilitate cross-regional, interdisciplinary cooperation among researchers. This decision was taken by the DFG Senate at its autumn meeting in Bonn. The new groups are intended to enable researchers to devote themselves to current and urgent issues within their fields and to develop new approaches.

15 Oct 2010

Officials address several drug issues including medical risks, proper disposal of unused medicine

Federal and state officials are addressing several drug issues including the risks associated with bone-strengthening drugs, complaints about a blood-thinning drug and a new law to help people safely dispose of unused medicine.

15 Oct 2010

Cancer cluster among Sydney Harbour Bridge workers triggers investigation

There are reports of a cancer cluster among Sydney Harbour Bridge workers with at least eight known cases that unions believe are linked to the use of lead paint. The Roads and Traffic Authority (RTA) will investigate the matter. Of the eight workers five have already died and all of them had been involved in painting and maintaining the bridge for more than 10 years, the Construction Forestry Mining and Energy Union (CFMEU) said. This included scraping off lead paint, initially with little protective equipment.

14 Oct 2010

First national educational conference on Graft vs. Host Disease

The Case Comprehensive Cancer Center, together with the Meredith A. Cowden Foundation, will bring the first national educational conference on Graft vs. Host Disease (GvHD) to Cleveland on Thursday, Nov. 4, 8 a.m. to 6 p.m., at Corporate College East, 4400 Richmond Road, Warrenville Hts. GvHD is a life-threatening complication experienced by an estimated 60 percent of all leukemia and other blood cancer patients following bone marrow transplantation. There is currently no cure.

14 Oct 2010

U.S. Bone and Joint Decade observes National Action Week

An annual global event, Bone and Joint National Action Week is held October 12-20 with activities focused on disorders including arthritis, back pain, osteoporosis, and the effects of childhood obesity on the musculoskeletal system. Events and projects organized worldwide are designed to raise awareness of prevention, disease management and treatments. In the United States, the U.S. Bone and Joint Decade represents the global initiative.

14 Oct 2010

Bone News and Research

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

Study: Half of Canadians with osteoporosis have insufficient levels of vitamin D

Study indicates vitamin D deficiency may increase lung transplant rejection

IBD patients with Vitamin D deficiency at greater risk of osteoporosis, osteopenia

FDA grants fast track designation for Aastrom's CLI cell therapy development program

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Nanotope enters agreement with Smith & Nephew to develop cartilage regeneration product

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

Women with normal bone mineral density at age 67 don't need osteoporosis screening again for 10 years

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Spinal fractures remain undiagnosed and untreated

CoreLab offers state-of-the-art imaging solutions for DXA imaging sciences

Childhood obesity impacts musculoskeletal system

DFG to establish new Research Units

Officials address several drug issues including medical risks, proper disposal of unused medicine

Cancer cluster among Sydney Harbour Bridge workers triggers investigation

First national educational conference on Graft vs. Host Disease

U.S. Bone and Joint Decade observes National Action Week

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News